Innovation Engineered at the Intersection of Life Sciences and Finance

Our Story

Launched in Switzerland in 2024, our team combines over 100 years of experience and proven expertise across clinical research, computer science, and finance.

Since 2016, we have pioneered a data-driven approach to indication finding—designed to accelerate development timelines, unlock asset value, and guide smarter, more informed strategic decisions. By integrating rigorous analytics with deep domain insights, we help life sciences partners and investors de-risk program development and navigate indication strategy with clarity and confidence.

Our Leadership

An operational team powered by NextGen tech and surrounded by industry experts

Team members:

Eric Mertz

Board Director

Visionary leader steering expansion

Rodrigo Hernandez Canteli

Board Director

Financial architect enabling sustainable growth

Marco Bocci

Chief Business Officer

Expert in identifying high-potential opportunities

Bernard Hamelin

Chief Medical Officer

Distinguished clinical development and medical affairs leader with over 25 years of international experience across therapeutic areas, including immunology, oncology, rare diseases, and cardiovascular medicine. He held senior roles at AstraZeneca and Sanofi, where he championed and pioneered the use of real-world evidence and digital platforms to speed clinical research and broaden market access for novel therapies. A recognized expert in applying advanced data analytics to pharmaceutical development and regulatory strategy, Bernard has led initiatives that shortened clinical timelines, strengthened evidence generation, and enhanced payer and regulatory engagement.

Advisors:

Michael Batech

Scientific Advisor

Pharmacoepidemiology strategist grounding R&D decisions in real‑world evidence

Jenaro Hernandez

Clinical Advisor

Ana de Lillo

Scientific Advisor

Ana Polanco

Board Advisor

Adrien Ramanana

Technology Advisor